

MATERIAL SAFETY DATA SHEET

Issued: 04/26/04
Revised: N/A
Revision: Original

Prepared by: Gary Wong
Manager EHS
Core No. 434

1. PRODUCT AND COMPANY INFORMATION

Product Name: Ofloxacin Ophthalmic Solution USP, 0.3%
Generic Name: Ofloxacin Ophthalmic Solution USP, 0.3%
NDC No. 24208-434-05 (5 ml)
24208-434-10 (10 ml)

Legal Category: Prescription only medicine, filled inside plastic bottle suitable for dispensing, and overpacked inside a cardboard carton.

Drug Composition: Anti-Infective

BAUSCH & LOMB INCORPORATED

8500 Hidden River Parkway

Tampa, FL 33637

Information: (800) 323-0000 (M-F) 8am-5pm EST

Emergency: (800) 227-1427 24 hrs

2. COMPOSITION/INFORMATION ON INGREDIENTS

Description	CAS #	TLV (mg/m ³)	PEL (mg/m ³)	% Content
Ofloxacin	82419-36-1	NE	NE	0.3%

Ingredients < 1% Sodium Chloride, Benzalkonium Chloride

3. HAZARDS IDENTIFICATION

EMERGENCY OVERVIEW

Plastic bottle in a cardboard box. Clear, greenish yellow aqueous solution. Presents little or no hazards if spilled and no unusual hazard if involved in fire.

POTENTIAL HEALTH HAZARDS

Carcinogenicity: (NTP) No (IARC) No (OSHA) No

Eye: May irritate the eyes.

Skin: Ofloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity reaction.

Ingestion: No data.

Inhalation: May irritate the respiratory tract.

Chronic Effects: Refer to Section 11.

Target Organs: None

Medical Conditions Aggravated by Long Term Exposure: The systemic administration of quinolones, including ofloxacin, has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropathy in immature animals of various species. Ofloxacin, administered systemically at 10 mg/kg/day in young dogs (equivalent to 110 times the maximum recommended daily adult ophthalmic dose) has been associated with these types of effects. Quinolones, including ofloxacin, have been shown to cause arthropathy in immature animals after oral administration; however, topical ocular administration of ofloxacin to immature animals has not shown any arthropathy. There is no evidence that the ophthalmic dosage form of ofloxacin has any effect on weight bearing joints.

4. FIRST AID MEASURES

Eyes: Rinse immediately with copious amounts of water for at least 20 minutes. Contact a physician.

Skin: Remove all contaminated clothing and wash skin with copious amounts of water for at least 20 minutes. Contact physician if skin becomes irritated.

Ingestion: Wash out mouth and drink plenty of water and bland fluids. The use of an emetic drug and/or gastric lavage is advisable. Do not give anything to an unconscious person. Contact physician.

Inhalation: Remove person to fresh air, and if breathing stops, use artificial respiration. Contact physician.

Note to Physicians: Additional details are available on the package insert or in the Physicians Desk Reference.

Pregnancy Category C: Ofloxacin has been shown to have an embryocidal effect in rats and in rabbits when given in doses of 810 mg/kg/day (equivalent to 9000 times the maximum recommended daily ophthalmic dose) and 160 mg/kg/day (equivalent to 1800 times the maximum recommended daily ophthalmic dose). These dosages resulted in decreased fetal body weight and increased fetal mortality in rats and rabbits, respectively. Minor fetal skeletal variations were reported in rats receiving doses of 810 mg/kg/day. Ofloxacin has not been shown to be teratogenic at doses as high as 810 mg/kg/day and 160 mg/kg/day when administered to pregnant rats and rabbits, respectively.

Nursing Mothers: In nursing women a single 200 mg oral dose resulted in concentrations of ofloxacin in milk which were similar to those found in plasma. It is not known whether ofloxacin is excreted in human milk following topical ophthalmic administration. Because of the potential for serious adverse reactions from ofloxacin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

5. FIRE FIGHTING MEASURES

Flammable Properties: Flash point: NE Method: NE

Hazardous Products: Products of combustion may be toxic.

Extinguishing Media: Dry chemical, carbon dioxide, halon, water spray or fog, and foam on surrounding materials.

Fire Fighting Instructions: Wear self-contained breathing apparatus and protective clothing. Use water spray to keep fire-exposed containers cool. Do not spray water into the burning material.

6. ACCIDENTAL RELEASE MEASURES

Large/Small Spills: Use personal protective equipment. Contain the spill to prevent drainage into sewers, drains or streams. Use absorbent material to solidify the spill. Shovel or scoop up solidified waste. Dispose of material according to Federal, State and Local regulations.

7. HANDLING AND STORAGE

Handling: Avoid contact with product and use caution to prevent puncturing containers. No special protective equipment or procedures are required in the clinical or home environment.

Storage: Store product upright in original containers with the cap tightly closed at a controlled room temperature 15⁰-25⁰ C (59⁰- 77⁰ F). **KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.**

8. EXPOSURE CONTROL/PERSONAL PROTECTION

Engineering Controls: In the manufacturing plant, provide adequate ventilation for the raw material handling and compounding process, which will maintain the dust and vapor, levels below the TLV, STEL, and PEL values for the ingredients. Ventilation fans should be explosion proof. Use adequate personal protective equipment e.g. NIOSH-approved respirators, goggles or safety glasses, gloves and protective clothing. Ensure training in the handling of chemical material and use current Material Safety Data Sheets.

Eye Protection: (29 CFR 1910.133) Recommend goggles or chemical safety glasses.

Skin Protection: Thick impermeable gloves and protective clothing.

Respiratory Protection: (29 CFR 1910.134) NIOSH approved respirator, with organic vapor, acid gas and HEPA filter recommended for handling raw materials.

Warning: Do not use air-purifying respirators in oxygen-depleted environments. No respiratory protection is required in the clinical or home environment.

Other: None

Ventilation: Recommended

Contaminated Equipment: Wash contaminated clothing separately. Wash contaminated equipment with soap and water. Release rinse water into an approved wastewater system or according to Federal, State and Local regulations.

9. CHEMICAL & PHYSICAL PROPERTIES

Appearance & Odor:	Greenish yellow aqueous solution		
Boiling Point:	NE	Evaporation Rate:	NE
Specific Gravity:	1.0	Vapor Density:	NE
Vapor Pressure:	NE	Viscosity:	NE
Water Solubility:	Complete	Percent Volatile by Volume:	<1

10. STABILITY AND REACTIVITY

Chemical Stability: Stable

Conditions to avoid: Extreme heat or cold.

Incompatibility: This product has the incompatibilities of water e.g. strong acids, bases, alkali metals, alkali hydrides and silver preparations.

Hazardous Decomposition Products: Products of combustion may be toxic.

Hazardous Polymerization: Should not occur.

11. TOXICOLOGY

Summary of Risks: Toxicological information refers to raw materials product. Concentrations and toxicological effects are substantially reduced in the product. For more detailed information see MSDS on chemical material

CAS #

82419-36-1

Ofloxacin

May cause asthenia, malaise, seizures, anxiety, cognitive change, vertigo, cough, bronchospasm, tachycardia, syncope, hepatic dysfunction, kidney dysfunction, and hypersensitivity reactions. Irritating to the eye, nose, and throat. Acute toxicity: LD50 (oral, rat) 3,590 mg/kg, TDLo (oral, male) 17 mg/kg/d, and TDLo (oral, female) 24 mg/kg/d. Reproductive toxicity: Embryotoxic in rats (160 mg/kg/d) and rabbits (810 mg/kg/d). Not teratogenic in rats and rabbits at 810 mg/kg/d. Pregnancy category C.

12. ECOLOGICAL INFORMATION

Chemical Fate Information: Product administered to patients presents a negligible impact on the environment.

13. DISPOAL INFORMATION

Dispose of material according to Federal, State, and Local regulations. The method typically used is incineration.

EPA Designations: RCRA Hazardous Waste: Not Listed

SARA Title III: Not Listed

14. TRANSPORTATION INFORMATION

Transportation Data: Not classified as hazardous by DOT regulations.

15. REGULATORY INFORMATION

- DOT Designations:** Not classified as hazardous by DOT regulations.
- EPA Designations:** RCRA Hazardous Waste
(40 CFR 261.33) Not Listed
- FDA Designations:** Prescription only medication.
NDC No. 24208-434-05 (5 ml)
24208-434-10 (10 ml)
- OSHA Designations:** (29 CFR 1910.1000, Table Z)
Not Listed
- SARA Title III:** Not listed under Section 313 of Toxic Release Reporting.
- CALIFORNIA PROPOSITION 65:** Not Listed

16. OTHER INFORMATION

None

The information contained herein is furnished without warranty of any kind. The above information is believed to be correct but does not purport to be all-inclusive and should be used only as a guide. Users should make independent determinations of the suitability and completeness of information from all sources to assure proper use and disposal of these materials and the safety and health of employees and customers.

NE- Not Established

< - Less Than

> - Greater Than